Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""adrenergic beta-2 receptor agonists"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 438
Tytuł:
Molecular determinants of ligand efficacy and potency in GPCR signaling.
Autorzy:
Heydenreich FM; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.; MRC Laboratory of Molecular Biology, Cambridge, UK.; Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.
Marti-Solano M; MRC Laboratory of Molecular Biology, Cambridge, UK.; Department of Pharmacology, University of Cambridge, Cambridge, UK.
Sandhu M; Department of Structural Biology and Center of Excellence for Data-Driven Discovery, St. Jude Children's Research Hospital, Memphis, TN, USA.
Kobilka BK; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Bouvier M; Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, QC, Canada.
Babu MM; MRC Laboratory of Molecular Biology, Cambridge, UK.; Department of Structural Biology and Center of Excellence for Data-Driven Discovery, St. Jude Children's Research Hospital, Memphis, TN, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2023 Dec 22; Vol. 382 (6677), pp. eadh1859. Date of Electronic Publication: 2023 Dec 22.
Typ publikacji:
Journal Article
MeSH Terms:
Adrenergic beta-2 Receptor Agonists*/chemistry
Adrenergic beta-2 Receptor Agonists*/pharmacology
Receptors, Adrenergic, beta-2*/chemistry
Receptors, Adrenergic, beta-2*/genetics
Humans ; Allosteric Regulation ; Biosensing Techniques ; Ligands ; Protein Conformation ; Signal Transduction ; Bioluminescence Resonance Energy Transfer Techniques
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Study protocol: A comparison of mobile and clinic-based spirometry for capturing the treatment effect in moderate asthma.
Autorzy:
Izmailova ES; Koneksa Health, New York, New York, USA.
Kilian R; Koneksa Health, New York, New York, USA.; SSI Strategy, New York, New York, USA.
Bakker JP; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Evans S; Koneksa Health, New York, New York, USA.; SSI Strategy, New York, New York, USA.
Scotina AD; Koneksa Health, New York, New York, USA.
Reiss TF; Independent Pharmaceutical Consultant, New Hope, Pennsylvania, USA.
Singh D; Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.
Wagner JA; Koneksa Health, New York, New York, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2023 Nov; Vol. 16 (11), pp. 2112-2122. Date of Electronic Publication: 2023 Sep 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Adrenergic beta-2 Receptor Agonists*/therapeutic use
Asthma*/diagnosis
Asthma*/drug therapy
Humans ; Forced Expiratory Volume ; Multicenter Studies as Topic ; Research Design ; Spirometry ; Clinical Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The effect of combining an inhaled corticosteroid and a long-acting muscarinic antagonist on human airway epithelial cells in vitro.
Autorzy:
Matera MG; Unit of Pharmacology, Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy. .
Rinaldi B; Unit of Pharmacology, Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Calabrese C; Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Belardo C; Unit of Pharmacology, Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Calzetta L; Respiratory Disease and Lung Function Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Cazzola M; Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy. .
Page C; Pulmonary Pharmacology Unit, Institute of Pharmaceutical Science, King's College, London, UK.
Pokaż więcej
Źródło:
Respiratory research [Respir Res] 2024 Feb 28; Vol. 25 (1), pp. 104. Date of Electronic Publication: 2024 Feb 28.
Typ publikacji:
Journal Article
MeSH Terms:
Asthma*/drug therapy
Pulmonary Disease, Chronic Obstructive*/drug therapy
Humans ; Muscarinic Antagonists/pharmacology ; Muscarinic Antagonists/therapeutic use ; NF-kappa B ; Interleukin-5 ; Adrenal Cortex Hormones/therapeutic use ; Administration, Inhalation ; Epithelial Cells ; Adrenergic beta-2 Receptor Agonists/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Exercise capacity and physical activity in COPD patients treated with a LAMA/LABA combination: a systematic review and meta-analysis.
Autorzy:
Miravitlles M; Pneumology Department, Hospital Universitari Vall d'HebronVall d'Hebron Institut de Recerca, Vall d'Hebron Barcelona Hospital Campus, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain. .
García-Rivero JL; Pneumology Department, President of ACINAR, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Ribera X; Boehringer Ingelheim España S.A., Barcelona, Spain.
Galera J; TFS Health Science, Barcelona, Spain.
García A; Market Access AreaPharmalex Spain, Barcelona, Spain.
Palomino R; Market Access AreaPharmalex Spain, Barcelona, Spain.
Pomares X; Pneumology Department, Hospital de Sabadell, Hospital Universitari Parc TaulíInstitut Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain.
Pokaż więcej
Źródło:
Respiratory research [Respir Res] 2022 Dec 15; Vol. 23 (1), pp. 347. Date of Electronic Publication: 2022 Dec 15.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Adrenergic beta-2 Receptor Agonists*
Pulmonary Disease, Chronic Obstructive*/diagnosis
Pulmonary Disease, Chronic Obstructive*/drug therapy
Pulmonary Disease, Chronic Obstructive*/etiology
Humans ; Exercise Tolerance ; Quality of Life ; Administration, Inhalation ; Muscarinic Antagonists ; Exercise ; Bronchodilator Agents ; Drug Combinations ; Drug Therapy, Combination ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea.
Autorzy:
Lee CH; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Kim MS; Medical Research Collaborating Center, Seoul National University Hospital, Seoul, South Korea.
Yeo SH; Value Evidence & Outcomes, GlaxoSmithKline, Singapore, Singapore.
Rhee CK; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Park HW; Department of Internal Medicine, Seoul National University, Seoul, South Korea.; Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, South Korea.; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
Yang BR; College of Pharmacy, Chungnam National University, Daejeon, South Korea.
Lee J; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, South Korea.
Cho EY; MA Respiratory Department, GlaxoSmithKline, Seoul, South Korea.
Xu X; Value Evidence & Outcomes, GlaxoSmithKline, Singapore, Singapore.
Navarro Rojas AA; Value Evidence & Outcomes, GlaxoSmithKline, Singapore, Singapore.
Shantakumar S; Value Evidence & Outcomes, GlaxoSmithKline, Singapore, Singapore.
Milea D; Value Evidence & Outcomes, GlaxoSmithKline, Singapore, Singapore.
Choi NK; Department of Health Convergence, College of Science and Industry Convergence, Ewha Womans University, Seoul, South Korea. .
Pokaż więcej
Źródło:
Respiratory research [Respir Res] 2022 Sep 05; Vol. 23 (1), pp. 231. Date of Electronic Publication: 2022 Sep 05.
Typ publikacji:
Journal Article
MeSH Terms:
Adrenergic beta-2 Receptor Agonists*
Pulmonary Disease, Chronic Obstructive*/diagnosis
Pulmonary Disease, Chronic Obstructive*/drug therapy
Pulmonary Disease, Chronic Obstructive*/epidemiology
Administration, Inhalation ; Adrenal Cortex Hormones ; Aged ; Bronchodilator Agents ; Female ; Humans ; Male ; Nebulizers and Vaporizers ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD 'real world' study.
Autorzy:
Vogelmeier CF; Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Giessen and Marburg, Philipps-University Marburg, Member of the German Centre for Lung Research (DZL), 35043, Marburg, Germany. .
Worth H; Facharztforum Fürth, 90762, Fürth, Germany.
Buhl R; Pulmonary Department, Mainz University Hospital, 55131, Mainz, Germany.
Criée CP; Department of Sleep and Respiratory Medicine, Evangelical Hospital Goettingen-Weende, 37120, Bovenden, Germany.
Gückel E; Clinical Research, Respiratory, Novartis Pharma GmbH, 90429, Nürnberg, Germany.
Kardos P; Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau Hospital, 60316, Frankfurt am Main, Germany.
Pokaż więcej
Źródło:
Respiratory research [Respir Res] 2022 May 02; Vol. 23 (1), pp. 109. Date of Electronic Publication: 2022 May 02.
Typ publikacji:
Journal Article
MeSH Terms:
Adrenergic beta-2 Receptor Agonists*/adverse effects
Pulmonary Disease, Chronic Obstructive*/complications
Pulmonary Disease, Chronic Obstructive*/diagnosis
Pulmonary Disease, Chronic Obstructive*/drug therapy
Administration, Inhalation ; Adrenal Cortex Hormones/adverse effects ; Drug Therapy, Combination ; Humans ; Muscarinic Antagonists/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN).
Autorzy:
Skloot GS; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy. .; Chiesi USA, Inc., Cary, NC, USA. .
Guasconi A; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Lavon BR; FLUIDDA, Kontich, Belgium.
Georges G; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
De Backer W; Department of Respiratory Medicine, University of Antwerp, Antwerp, Belgium.
Galkin D; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Cortellini M; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Panni I; Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Bates JHT; Departments of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Pokaż więcej
Źródło:
Respiratory research [Respir Res] 2023 Oct 06; Vol. 24 (1), pp. 244. Date of Electronic Publication: 2023 Oct 06.
Typ publikacji:
Journal Article
MeSH Terms:
Glycopyrrolate*
Pulmonary Disease, Chronic Obstructive*/diagnostic imaging
Pulmonary Disease, Chronic Obstructive*/drug therapy
Humans ; Formoterol Fumarate ; Beclomethasone ; Muscarinic Antagonists ; Administration, Inhalation ; Fluticasone-Salmeterol Drug Combination ; Drug Combinations ; Adrenergic beta-2 Receptor Agonists ; Bronchodilator Agents
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Severity distribution and treatment of chronic obstructive pulmonary disease in China: baseline results of an observational study.
Autorzy:
Yang T; Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.; National Clinical Research Center for Respiratory Diseases, Beijing, 100029, China.
Cai B; Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing, China.
Cao B; Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.; National Clinical Research Center for Respiratory Diseases, Beijing, 100029, China.
Kang J; Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, China.
Wen F; Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
Chen Y; Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China.
Jian W; State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, National Clinical Research Center for Respiratory Disease, 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Shang H; Department of Medical Affairs, AstraZeneca China, Shanghai, China.
Wang C; Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, 100029, China. .; National Clinical Research Center for Respiratory Diseases, Beijing, 100029, China. .
Pokaż więcej
Źródło:
Respiratory research [Respir Res] 2022 Apr 29; Vol. 23 (1), pp. 106. Date of Electronic Publication: 2022 Apr 29.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Adrenergic beta-2 Receptor Agonists*
Pulmonary Disease, Chronic Obstructive*/diagnosis
Pulmonary Disease, Chronic Obstructive*/drug therapy
Pulmonary Disease, Chronic Obstructive*/epidemiology
Administration, Inhalation ; Humans ; Muscarinic Antagonists/therapeutic use ; Prospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Characteristics of COPD patients treated with single‑inhaler triple therapy in real-life clinical practice.
Autorzy:
Lassan S
Keszegh J
Lassanova M
Pokaż więcej
Źródło:
Bratislavske lekarske listy [Bratisl Lek Listy] 2022; Vol. 123 (1), pp. 27-36.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Adrenergic beta-2 Receptor Agonists*/therapeutic use
Pulmonary Disease, Chronic Obstructive*/drug therapy
Administration, Inhalation ; Adrenal Cortex Hormones/therapeutic use ; Cross-Sectional Studies ; Drug Therapy, Combination ; Humans ; Muscarinic Antagonists/therapeutic use ; Nebulizers and Vaporizers ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Autorzy:
Usmani O; Asthma Lab, National Heart and Lung Institute (NHLI), Imperial College London & Royal Brompton Hospital, South Block, Royal Brompton Campus, Sydney St, Chelsea, London, SW3 6NP, UK. .
Roche N; Respiratory Medicine, Hôpital Cochin (AP-HP), University of Paris, Cochin Institute, Paris, France.
Wahab E; Simbec Research Ltd, Merthyr Tydfil, UK.
Israel S; Simbec Research Ltd, Merthyr Tydfil, UK.
Jenkins M; AstraZeneca, Cambridge, UK.
Trivedi R; AstraZeneca, Durham, NC, USA.
Dorinsky P; AstraZeneca, Durham, NC, USA.
Aurivillius M; AstraZeneca, Gothenburg, Sweden.
Pokaż więcej
Źródło:
Respiratory research [Respir Res] 2021 Oct 07; Vol. 22 (1), pp. 261. Date of Electronic Publication: 2021 Oct 07.
Typ publikacji:
Clinical Trial, Phase I; Journal Article
MeSH Terms:
Adrenergic beta-2 Receptor Agonists*/administration & dosage
Adrenergic beta-2 Receptor Agonists*/adverse effects
Bronchodilator Agents*/administration & dosage
Bronchodilator Agents*/adverse effects
Glucocorticoids*/administration & dosage
Glucocorticoids*/adverse effects
Lung*/diagnostic imaging
Lung*/drug effects
Lung*/physiopathology
Muscarinic Antagonists*/administration & dosage
Muscarinic Antagonists*/adverse effects
Pulmonary Disease, Chronic Obstructive*/diagnostic imaging
Pulmonary Disease, Chronic Obstructive*/drug therapy
Pulmonary Disease, Chronic Obstructive*/physiopathology
Aged ; Female ; Humans ; Male ; Middle Aged ; Administration, Inhalation ; Contrast Media ; Metered Dose Inhalers ; Predictive Value of Tests ; Radionuclide Imaging ; Recovery of Function ; Severity of Illness Index ; Sodium Pertechnetate Tc 99m ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial.
Autorzy:
Vogelmeier CF; Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Giessen and Marburg, Philipps-Universität Marburg, German Centre for Lung Research (DZL), Baldingerstraße, 35043, Marburg, Germany. .
Jones PW; GSK, Brentford, Middlesex, UK.
Kerwin EM; Altitude Clinical Consulting and Clinical Research Institute of Southern Oregon, Medford, OR, USA.
Boucot IH; GSK, Brentford, Middlesex, UK.
Maltais F; Centre de Pneumologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Québec, Canada.
Tombs L; Precise Approach Ltd, GSK, Brentford, Middlesex, UK.
Compton C; GSK, Brentford, Middlesex, UK.
Lipson DA; Respiratory Clinical Sciences, GSK, Collegeville, PA, USA.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Bjermer LH; Respiratory Medicine and Allergology, Lund University, Lund, Sweden.
Pokaż więcej
Źródło:
Respiratory research [Respir Res] 2021 Oct 28; Vol. 22 (1), pp. 279. Date of Electronic Publication: 2021 Oct 28.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Adrenergic beta-2 Receptor Agonists/*administration & dosage
Benzyl Alcohols/*administration & dosage
Bronchodilator Agents/*administration & dosage
Chlorobenzenes/*administration & dosage
Lung/*drug effects
Muscarinic Antagonists/*administration & dosage
Pulmonary Disease, Chronic Obstructive/*drug therapy
Quinuclidines/*administration & dosage
Adrenergic beta-2 Receptor Agonists/adverse effects ; Aged ; Benzyl Alcohols/adverse effects ; Bronchodilator Agents/adverse effects ; Chlorobenzenes/adverse effects ; Double-Blind Method ; Drug Combinations ; Female ; Forced Expiratory Volume ; Humans ; Lung/physiopathology ; Male ; Middle Aged ; Muscarinic Antagonists/adverse effects ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Quinuclidines/adverse effects ; Recovery of Function ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Extrafine HFA-beclomethasone-formoterol vs. nonextrafine combination of an inhaled corticosteroid and a long acting β2-agonist in patients with persistent asthma: A systematic review and meta-analysis.
Autorzy:
Liu T; Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, Chengdu Province, China.
Yang D; Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, Chengdu Province, China.
Liu C; Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, Chengdu Province, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2021 Sep 03; Vol. 16 (9), pp. e0257075. Date of Electronic Publication: 2021 Sep 03 (Print Publication: 2021).
Typ publikacji:
Comparative Study; Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Adrenal Cortex Hormones/*therapeutic use
Adrenergic beta-2 Receptor Agonists/*therapeutic use
Asthma/*drug therapy
Beclomethasone/*therapeutic use
Formoterol Fumarate/*therapeutic use
Hydrocarbons, Fluorinated/*therapeutic use
Administration, Inhalation ; Adolescent ; Adrenal Cortex Hormones/administration & dosage ; Adrenal Cortex Hormones/adverse effects ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Adult ; Aged ; Beclomethasone/adverse effects ; Female ; Formoterol Fumarate/adverse effects ; Humans ; Hydrocarbons, Fluorinated/adverse effects ; Male ; Middle Aged ; Outcome Assessment, Health Care ; Publication Bias ; Risk ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical Characteristics and Economic Burden of Asthma in China: A Multicenter Retrospective Study.
Autorzy:
Shang B; Department of Thoracic Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China AND Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. .
Li X; Department of Pulmonary and Critical Care Medicine, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China AND Department of Pulmonary and Critical Care Medicine, The Affiliated Wenling Hospital of Wenzhou Medical University, Taizhou, China. .
Xu Y; Department of Pulmonary and Critical Care Medicine, Shandong Provincial Hospital, Affiliated to Shandong First Medical University, Jinan, China AND Department of Pulmonary and Critical Care Medicine, Jinan Shizhong People's Hospital, Jinan, China. .
Ren W; Department of Pulmonary and Critical Care Medicine, Shandong Provincial Hospital, Affiliated to Shandong First Medical University, Jinan, China AND Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, China. .
Wang J; Department of Pulmonary and Critical Care Medicine, Shandong Provincial Hospital, Affiliated to Shandong First Medical University, Jinan, China AND Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, China. .
Xing C; Department of Pulmonary and Critical Care Medicine, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, China. chunyanxing_.
Jiang S; Department of Pulmonary and Critical Care Medicine, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China AND Department of Pulmonary and Critical Care Medicine, Shandong Provincial Hospital, Affiliated to Shandong First Medical University, Jinan, China. .
Sun J; Department of Pulmonary and Critical Care Medicine, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China AND Department of Pulmonary and Critical Care Medicine, Shandong Provincial Hospital, Affiliated to Shandong First Medical University, Jinan, Ch. .
Pokaż więcej
Źródło:
Iranian journal of allergy, asthma, and immunology [Iran J Allergy Asthma Immunol] 2023 Jun 16; Vol. 22 (3), pp. 290-298. Date of Electronic Publication: 2023 Jun 16.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Asthma*/drug therapy
Asthma*/epidemiology
Pulmonary Disease, Chronic Obstructive*
Humans ; Retrospective Studies ; Financial Stress ; Administration, Inhalation ; Adrenal Cortex Hormones/therapeutic use ; Adrenergic beta-2 Receptor Agonists ; Drug Therapy, Combination
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
[COPD - An Underestimated Disease].
Autorzy:
Leuppi JD; Universitäres Zentrum Innere Medizin, Kantonsspital Baselland, Liestal, Schweiz.; Medizinische Fakultät, Universität Basel, Basel, Schweiz.
Bridevaux PO; Service de pneumologie, Centre Hospitalier du Valais Romand, Hôpital du Valais, Sion, Schweiz.; Service de pneumologie, Hôpitaux Universitaires de Genève, Genf, Schweiz.; Faculty of medicine, University of Geneva, Genf, Schweiz.
Charbonnier F; Service de pneumologie, Hôpitaux Universitaires de Genève, Genf, Schweiz.
Clarenbach CF; Klinik für Pneumologie, Universitätsspital Zürich, Universität Zürich, Zürich, Schweiz.
Duchna HW; Hochgebirgsklinik Davos, Davos, Schweiz.
Fellrath JM; Service de Pneumologie, Département de médecine. Réseau Hospitalier Neuchâtelois; Neuchâtel, Schweiz.
Gianella P; Servizio di Pneumologia, Ospedale Regionale di Lugano, Lugano, Schweiz.
Jochmann A; Pädiatrische Pneumologie, Universitätskinderspital beider Basel, Basel, Schweiz.
Kern L; Klinik für Pneumologie und Schlafmedizin, Kantonsspital St. Gallen, St. Gallen, Schweiz.
Pavlov N; Universitätsklinik für Pneumologie, Inselspital, Universitätsspital Bern, Universität Bern, Bern, Schweiz.
Rothe T; Pneumologie/Schlafmedizin, Kantonsspital Graubünden, Chur, Schweiz.; Pneumologie, Spital Davos, Davos, Schweiz.
Steurer-Stey C; Institut für Epidemiologie, Biostatistik und Prävention, Universität Zürich, Zürich, Schweiz.; mediX Gruppenpraxis Zürich, Zürich, Schweiz.
von Garnier C; Service de Pneumologie, Centre Hospitalier Universitaire Vaudois, Université de Lausanne, Lausanne, Schweiz.
Pokaż więcej
Transliterated Title:
COPD – eine unterschätzte Erkrankung.
Źródło:
Praxis [Praxis (Bern 1994)] 2023 Jun; Vol. 112 (7-8), pp. 403-412.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Bronchodilator Agents*/therapeutic use
Pulmonary Disease, Chronic Obstructive*/therapy
Pulmonary Disease, Chronic Obstructive*/drug therapy
Humans ; Drug Therapy, Combination ; Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/therapeutic use ; Adrenal Cortex Hormones/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD.
Autorzy:
Lee EG; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Kim Y; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Konkuk University Hospital, School of Medicine, Konkuk University, Seoul, South Korea.
Hwang YI; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang-Si, Gyeonggi-Do, South Korea.
Yoo KH; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Konkuk University Hospital, School of Medicine, Konkuk University, Seoul, South Korea.
Lee SE; Medical Affairs, Boehringer-Ingelheim, Seoul, South Korea.
Jung KY; Medical Affairs, Boehringer-Ingelheim, Seoul, South Korea.
Lee D; Real-World Solutions, IQVIA, Seoul, South Korea.
Park YB; Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Seoul, South Korea.
Rhee CK; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-Gu, Seoul, 06591, South Korea. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 May 20; Vol. 13 (1), pp. 8183. Date of Electronic Publication: 2023 May 20.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Pulmonary Disease, Chronic Obstructive*/complications
Pulmonary Disease, Chronic Obstructive*/drug therapy
Pulmonary Disease, Chronic Obstructive*/epidemiology
Pneumonia*/drug therapy
Humans ; Muscarinic Antagonists/adverse effects ; Incidence ; Cohort Studies ; Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Adrenal Cortex Hormones/adverse effects ; Drug Therapy, Combination ; Bronchodilator Agents
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
Autorzy:
Zheng J; State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Baldi S; Global Clinical Development, Chiesi Farmaceutici SpA, Largo Belloli, 11\a, 43122, Parma, Italy.
Zhao L; Shengjing Hospital of China Medical University, Shenyang, China.
Li H; Shanghai Pulmonary Hospital, Shanghai, China.
Lee KH; Yeungnam University Medical Center, Daegu, Republic of Korea.
Singh D; Medicines Evaluation Unit, The University of Manchester, Manchester University NHS Foundations Trust, Manchester, UK.
Papi A; Respiratory Medicine Unit, University of Ferrara, University Hospital S. Anna, Ferrara, Italy.
Grapin F; Global Clinical Development, Chiesi Farmaceutici SpA, Largo Belloli, 11\a, 43122, Parma, Italy.
Guasconi A; Global Clinical Development, Chiesi Farmaceutici SpA, Largo Belloli, 11\a, 43122, Parma, Italy.
Georges G; Global Clinical Development, Chiesi Farmaceutici SpA, Largo Belloli, 11\a, 43122, Parma, Italy. .
Pokaż więcej
Źródło:
Respiratory research [Respir Res] 2021 Mar 23; Vol. 22 (1), pp. 90. Date of Electronic Publication: 2021 Mar 23.
Typ publikacji:
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Adrenergic beta-2 Receptor Agonists/*administration & dosage
Beclomethasone/*administration & dosage
Bronchodilator Agents/*administration & dosage
Formoterol Fumarate/*administration & dosage
Glucocorticoids/*administration & dosage
Glycopyrrolate/*administration & dosage
Lung/*drug effects
Muscarinic Antagonists/*administration & dosage
Pulmonary Disease, Chronic Obstructive/*drug therapy
Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Aged ; Beclomethasone/adverse effects ; Bronchodilator Agents/adverse effects ; China ; Disease Progression ; Double-Blind Method ; Drug Combinations ; Dry Powder Inhalers ; Female ; Forced Expiratory Volume ; Formoterol Fumarate/adverse effects ; Glucocorticoids/adverse effects ; Glycopyrrolate/adverse effects ; Humans ; Lung/physiopathology ; Male ; Middle Aged ; Muscarinic Antagonists/adverse effects ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Recovery of Function ; Republic of Korea ; Taiwan ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The impact of impaired sleep quality on symptom change and future exacerbation of chronic obstructive pulmonary disease.
Autorzy:
Lin L; Department of Respiratory and Critical Care Medicine, Second Xiangya Hospital, Central South University, 139 Renmin Middle Road, Changsha, Hunan, 410011, China.; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.
Song Q; Department of Respiratory and Critical Care Medicine, Second Xiangya Hospital, Central South University, 139 Renmin Middle Road, Changsha, Hunan, 410011, China.; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.
Duan J; Geriatrics Department, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Liu C; Department of Respiratory and Critical Care Medicine, Second Xiangya Hospital, Central South University, 139 Renmin Middle Road, Changsha, Hunan, 410011, China.; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.
Cheng W; Department of Respiratory and Critical Care Medicine, Second Xiangya Hospital, Central South University, 139 Renmin Middle Road, Changsha, Hunan, 410011, China.; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.
Zhou A; Center of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Peng Y; Department of Respiratory and Critical Care Medicine, Second Xiangya Hospital, Central South University, 139 Renmin Middle Road, Changsha, Hunan, 410011, China.; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.
Zhou Z; Department of Respiratory and Critical Care Medicine, Second Xiangya Hospital, Central South University, 139 Renmin Middle Road, Changsha, Hunan, 410011, China.; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.
Zeng Y; Department of Respiratory and Critical Care Medicine, Second Xiangya Hospital, Central South University, 139 Renmin Middle Road, Changsha, Hunan, 410011, China.; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.
Chen Y; Department of Respiratory and Critical Care Medicine, Second Xiangya Hospital, Central South University, 139 Renmin Middle Road, Changsha, Hunan, 410011, China.; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.
Cai S; Department of Respiratory and Critical Care Medicine, Second Xiangya Hospital, Central South University, 139 Renmin Middle Road, Changsha, Hunan, 410011, China.; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China.
Chen P; Department of Respiratory and Critical Care Medicine, Second Xiangya Hospital, Central South University, 139 Renmin Middle Road, Changsha, Hunan, 410011, China. .; Research Unit of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China. .; Diagnosis and Treatment Center of Respiratory Disease, Central South University, Changsha, Hunan, 410011, China. .
Pokaż więcej
Źródło:
Respiratory research [Respir Res] 2023 Mar 30; Vol. 24 (1), pp. 98. Date of Electronic Publication: 2023 Mar 30.
Typ publikacji:
Journal Article
MeSH Terms:
Sleep Quality*
Pulmonary Disease, Chronic Obstructive*/diagnosis
Pulmonary Disease, Chronic Obstructive*/epidemiology
Pulmonary Disease, Chronic Obstructive*/drug therapy
Humans ; Prospective Studies ; Disease Progression ; Risk Factors ; Adrenergic beta-2 Receptor Agonists ; Muscarinic Antagonists ; Administration, Inhalation ; Adrenal Cortex Hormones
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Systemic administration of a β2-adrenergic receptor agonist reduces mechanical allodynia and suppresses the immune response to surgery in a rat model of persistent post-incisional hypersensitivity.
Autorzy:
Arora V; Department of Neural and Pain Sciences, School of Dentistry, University of Maryland, Baltimore, MD, USA.
Morado-Urbina CE; Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Gwak YS; Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Parker RA; Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Kittel CA; Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Munoz-Islas E; Universidad Autónoma de Tamaulipas, Reynosa, Tamaulipas, Mexico.
Miguel Jimenez-Andrade J; Universidad Autónoma de Tamaulipas, Reynosa, Tamaulipas, Mexico.
Romero-Sandoval EA; Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Eisenach JC; FM James III Professor of Anesthesiology and Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Peters CM; Department of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Pokaż więcej
Źródło:
Molecular pain [Mol Pain] 2021 Jan-Dec; Vol. 17, pp. 1744806921997206.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Adrenergic beta-2 Receptor Agonists/*therapeutic use
Clenbuterol/*therapeutic use
Hyperalgesia/*drug therapy
Immunity/*drug effects
Microglia/*drug effects
Pain, Postoperative/*drug therapy
Surgical Wound/*complications
Adrenergic beta-2 Receptor Agonists/pharmacology ; Animals ; Clenbuterol/pharmacology ; Hyperalgesia/etiology ; Hyperalgesia/immunology ; Male ; Neurons/drug effects ; Pain, Postoperative/etiology ; Pain, Postoperative/immunology ; Rats ; Rats, Sprague-Dawley
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids.
Autorzy:
Huang TM; Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Kuo KC; Division of Pulmonary, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
Wang YH; Medical Research Center, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Wang CY; Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Lai CC; Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan. .
Wang HC; Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. .
Chen L; Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Miaoli County, Taiwan.
Yu CJ; Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.
Pokaż więcej
Corporate Authors:
On the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE)
Źródło:
BMC infectious diseases [BMC Infect Dis] 2020 Sep 25; Vol. 20 (1), pp. 706. Date of Electronic Publication: 2020 Sep 25.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Mycobacterium tuberculosis*
Adrenal Cortex Hormones/*therapeutic use
Adrenergic beta-2 Receptor Agonists/*therapeutic use
Budesonide, Formoterol Fumarate Drug Combination/*therapeutic use
Fluticasone-Salmeterol Drug Combination/*therapeutic use
Pulmonary Disease, Chronic Obstructive/*drug therapy
Tuberculosis/*epidemiology
Administration, Inhalation ; Adrenal Cortex Hormones/administration & dosage ; Adrenal Cortex Hormones/adverse effects ; Adrenergic beta-2 Receptor Agonists/administration & dosage ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Aged ; Budesonide, Formoterol Fumarate Drug Combination/administration & dosage ; Budesonide, Formoterol Fumarate Drug Combination/adverse effects ; Female ; Fluticasone-Salmeterol Drug Combination/administration & dosage ; Fluticasone-Salmeterol Drug Combination/adverse effects ; Follow-Up Studies ; Humans ; Incidence ; Male ; Middle Aged ; Propensity Score ; Risk Factors ; Taiwan/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator.
Autorzy:
Jimenez E; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, 08020, Barcelona, Spain. .
Astbury C; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Albayaty M; Early Phase Clinical Unit, PAREXEL International GmbH, Harrow, UK.
Wählby-Hamrén U; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Seoane B; Biometrics and Information Sciences, Late-Stage Development, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Villarroel C; Late-Stage Development, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Pujol H; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Bermejo MJ; Patient Safety, Chief Medical Office, R&D, AstraZeneca, Barcelona, Spain.
Aggarwal A; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Psallidas I; Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Pokaż więcej
Źródło:
Respiratory research [Respir Res] 2020 Sep 09; Vol. 21 (Suppl 1), pp. 211. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
MeSH Terms:
Adrenergic beta-2 Receptor Agonists/*administration & dosage
Asthma/*drug therapy
Bronchoconstriction/*drug effects
Bronchodilator Agents/*administration & dosage
Lung/*drug effects
Muscarinic Antagonists/*administration & dosage
Quinolines/*administration & dosage
Triazoles/*administration & dosage
Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Adrenergic beta-2 Receptor Agonists/pharmacokinetics ; Adult ; Asthma/diagnosis ; Asthma/physiopathology ; Bronchodilator Agents/adverse effects ; Bronchodilator Agents/pharmacokinetics ; England ; Female ; Forced Expiratory Volume ; Humans ; Lung/physiopathology ; Male ; Middle Aged ; Muscarinic Antagonists/adverse effects ; Muscarinic Antagonists/pharmacokinetics ; Quinolines/adverse effects ; Quinolines/pharmacokinetics ; Recovery of Function ; Severity of Illness Index ; Single-Blind Method ; Treatment Outcome ; Triazoles/adverse effects ; Triazoles/pharmacokinetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 438

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies